Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
IDERA PHARMACEUTICALS INC (IDRA) Stock Price & Overview
NASDAQ:IDRA • US45168K4058
Current stock price
0.425 USD
-0.12 (-21.57%)
At close:
0.42 USD
-0.01 (-1.18%)
After Hours:
The current stock price of IDRA is 0.425 USD. Today IDRA is down by -21.57%. In the past month the price increased by 54.55%. In the past year, price decreased by -28.08%.
IDRA Key Statistics
52-Week Range0.215 - 0.7899
Current IDRA stock price positioned within its 52-week range.
1-Month Range0.215 - 0.72
Current IDRA stock price positioned within its 1-month range.
- Market Cap
- 25.083M
- P/E
- 0.18
- Fwd P/E
- N/A
- EPS (TTM)
- 2.34
- Dividend Yield
- N/A
IDRA Stock Performance
Today
-21.57%
1 Week
-35.11%
1 Month
+54.55%
3 Months
+8.97%
Longer-term
6 Months +6.25%
1 Year -28.08%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
IDRA Stock Chart
IDRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IDRA. When comparing the yearly performance of all stocks, IDRA is a bad performer in the overall market: 74.57% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
IDRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IDRA. IDRA may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IDRA Earnings
Next Earnings DateMar 29, 2023
Last Earnings DateN/A
PeriodQ3 / 2022
EPS Reported-$0.06
Revenue Reported
EPS Surprise %
Revenue Surprise %
IDRA Forecast & Estimates
Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
IDRA Financial Highlights
Over the last trailing twelve months IDRA reported a non-GAAP Earnings per Share(EPS) of 2.34. The EPS increased by 160.78% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-17.85M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%45.45%
Sales Q2Q%N/A
EPS 1Y (TTM)160.78%
Revenue 1Y (TTM)N/A
IDRA Ownership
Ownership
Inst OwnersN/A
Shares59.02M
Float43.64M
Ins Owners11.98%
Short Float %N/A
Short RatioN/A
IDRA Industry Overview
IDRA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.8%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.1
IDRA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IDRA
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
Company Info
IPO: 1996-01-25
IDERA PHARMACEUTICALS INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA 19341 US
CEO: Vincent J. Milano
Employees: 13
Phone: 14843481600.0
IDERA PHARMACEUTICALS INC / IDRA FAQ
What does IDRA do?
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
What is the stock price of IDERA PHARMACEUTICALS INC today?
The current stock price of IDRA is 0.425 USD. The price decreased by -21.57% in the last trading session.
Does IDERA PHARMACEUTICALS INC pay dividends?
IDRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IDRA stock?
IDRA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does IDERA PHARMACEUTICALS INC (IDRA) report earnings?
IDERA PHARMACEUTICALS INC (IDRA) will report earnings on 2023-03-29.
Who owns IDERA PHARMACEUTICALS INC?
You can find the ownership structure of IDERA PHARMACEUTICALS INC (IDRA) on the Ownership tab.